VG
Indication: Alzheimer's disease
Interactive VG-3927 PK/PD simulator for Alzheimer's disease. VG-3927 is an oral small-molecule TREM2 agonist designed to activate microglial TREM2 signaling; this model reconstructs phase 1 plasma PK, CSF exposure, and sTREM2 biomarker suppression from AAIC 2025 sponsor data.
Drug Overview
Clinical Context
- Molecular Target
- TREM2
- Drug Class
- Oral small-molecule TREM2 agonist
- Therapeutic Area
- Alzheimer's disease
- Indication
- Alzheimer's disease
- Route of Administration
- Oral
Model Information
- Model Type
- Pragmatic two-compartment oral PK model with a CSF-linked indirect inhibition hysteresis PD layer for sTREM2
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for VG allows you to explore concentration-time profiles under different dosing scenarios. The underlying Pragmatic two-compartment oral PK model with a CSF-linked indirect inhibition hysteresis PD layer for sTREM2 model characterizes the pharmacokinetics of this oral small-molecule trem2 agonist following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the VG PK simulator?
This is a free, interactive pharmacokinetic simulator for VG used in Alzheimer's disease. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does VG belong to?
VG is classified as a Oral small-molecule TREM2 agonist that targets TREM2. It is used in the Alzheimer's disease therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of VG. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Pragmatic two-compartment oral PK model with a CSF-linked indirect inhibition hysteresis PD layer for sTREM2 model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the VG simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community